18 May 2018
Interestingly, nobody had ever asked to which degree the polymeric carrier of a nanomedicine would accumulate in the brain assuming that the nanomedicine would be applied chronically and the carrier is slowly broken down.
Celine Bolwerk, Larissa Govers and Hanna Knol, under supervision of Roland Brock and Thom Oostendorp, theme Nanomedicine, answered this question in the context of their second year bachelor research project.
The results were recently published in ChemMedChem.
Nanomedicines hold great promise in the development of new therapies also for disorders of the central nervous system.
Interestingly, nobody had ever asked to which degree the polymeric carrier of a nanomedicine would accumulate in the brain assuming that the nanomedicine would be applied chronically and the carrier is slowly broken down.
Celine Bolwerk, Larissa Govers and Hanna Knol, under supervision of Roland Brock and Thom Oostendorp, theme Nanomedicine, answered this question in the context of their second year bachelor research project.
The results were recently published in ChemMedChem.